212 related articles for article (PubMed ID: 21269826)
1. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
[TBL] [Abstract][Full Text] [Related]
2. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
[TBL] [Abstract][Full Text] [Related]
3. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
[TBL] [Abstract][Full Text] [Related]
7. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
Han F; Lin S; Liu P; Tao J; Yi C; Xu H
Bioorg Med Chem Lett; 2014 Sep; 24(18):4538-4541. PubMed ID: 25139570
[TBL] [Abstract][Full Text] [Related]
9. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
Herrera VA; Zeindl-Eberhart E; Jung A; Huber RM; Bergner A
Anticancer Res; 2011 Mar; 31(3):849-54. PubMed ID: 21498705
[TBL] [Abstract][Full Text] [Related]
10. Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.
Liu KK; Bailey S; Dinh DM; Lam H; Li C; Wells PA; Yin MJ; Zou A
Bioorg Med Chem Lett; 2012 Aug; 22(15):5114-7. PubMed ID: 22765900
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation.
Ma X; Lv X; Qiu N; Yang B; He Q; Hu Y
Bioorg Med Chem; 2015 Dec; 23(24):7585-96. PubMed ID: 26596710
[TBL] [Abstract][Full Text] [Related]
12. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
14. Entry into a new class of protein kinase inhibitors by pseudo ring design.
Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J
Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988
[TBL] [Abstract][Full Text] [Related]
15. The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.
Stec MM; Andrews KL; Bo Y; Caenepeel S; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Whittington DA; Wang L; Wu T; Zalameda LP; Zhang N; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2015 Oct; 25(19):4136-42. PubMed ID: 26298499
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.
Lin S; Han F; Liu P; Tao J; Zhong X; Liu X; Yi C; Xu H
Bioorg Med Chem Lett; 2014 Feb; 24(3):790-3. PubMed ID: 24433860
[TBL] [Abstract][Full Text] [Related]
18. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.
Finlay MR; Buttar D; Critchlow SE; Dishington AP; Fillery SM; Fisher E; Glossop SC; Graham MA; Johnson T; Lamont GM; Mutton S; Perkins P; Pike KG; Slater AM
Bioorg Med Chem Lett; 2012 Jun; 22(12):4163-8. PubMed ID: 22607682
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
Van Aller GS; Carson JD; Tang W; Peng H; Zhao L; Copeland RA; Tummino PJ; Luo L
Biochem Biophys Res Commun; 2011 Mar; 406(2):194-9. PubMed ID: 21300025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]